StockNews.AI
GUTS
StockNews.AI
176 days

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

1. Fractyl Health to report Q4 and full-year 2024 financials on Mar 3, 2025. 2. Business updates will be shared during a live conference call webcast. 3. Company focuses on innovative metabolic therapies for obesity and T2D. 4. Webcast details and replay available on the investor relations website.

3m saved
Insight
Article

FAQ

Why Neutral?

Earnings announcements usually trigger near-term volatility but are typically already priced in. Historical biotech earnings events often show minimal price movement until detailed results are released.

How important is it?

This scheduled earnings and update call is standard, making it moderately impactful with potential for short-term volatility.

Why Short Term?

Earnings reports create immediate market reactions. Past biotech announcements have led to short-term price adjustments without long-term shifts on announcement alone.

Related Companies

BURLINGTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering pattern breaking approaches for the treatment of obesity and type 2 diabetes (T2D), today announced it will report financial results for the fourth quarter and full year 2024 and provide business updates on Monday, March 3, 2025, at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the “Events” section of Fractyl’s website at https://ir.fractyl.com/. The webcast will be archived and available for replay following the live event. About Fractyl Health Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com. Contacts  Media Contact Jessica Cotrone, Head of Corporate Communicationsjcotrone@fractyl.com. 978.760.5622 Investor ContactBrian Luque, Head of Investor Relations and Corporate DevelopmentIR@fractyl.com, 951.206.1200

Related News